Benzinga106d agoneutral
FDA Panel Narrowly Backs Four Peptides - Hims & Hers Stock in the SpotlightNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
109last 24h
3127last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Simply Wall St.107d agoneutral
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% RunSimply Wall St.107d agoneutral
Does FDA Peptide Shift and CAO Exit Reframe the Bull Case for Hims & Hers Health (HIMS)?Simply Wall St.108d agoneutral
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide?Barrons.com108d agoneutral
What the FDA’s Peptide Decision Means for Hims & Hers’ Long-Term Telehealth StrategyInvestor's Business Daily108d agoneutral
Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds HigherStocktwits110d agoneutral
HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide MeetingInvestor's Business Daily115d agoneutral
This Trade Offers Two Ways To Profit From Hims & Hers StockStocktwits118d agoneutral
HIMS Stock Logs Worst Week In 2 Months - Turns To Peptides Campaign Ahead Of Key FDA MeetingSimply Wall St.125d agoneutral
Hims & Hers (HIMS) Stock May Be Undervalued After FDA Peptide QuestionsMotley Fool125d agobullish
Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?MarketBeat125d agobearish
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the WinnerBarrons.com126d agobullish
Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?